Candel Therapeutics, Inc. (CADL)
NASDAQ: CADL · Real-Time Price · USD
4.810
+0.050 (1.05%)
At close: May 9, 2025, 4:00 PM
4.860
+0.050 (1.04%)
After-hours: May 9, 2025, 7:09 PM EDT
Candel Therapeutics Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
38
Market Cap
236.99M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 410.06B |
| Johnson & Johnson | 89.33B |
| Merck & Co. | 63.92B |
| AbbVie | 57.37B |
| AstraZeneca | 54.98B |
| Novartis AG | 53.22B |
| Eli Lilly and Company | 49.00B |
| Novo Nordisk | 43.92B |
CADL News
- 4 days ago - Candel Therapeutics to Present at Upcoming Investor Conferences - GlobeNewsWire
- 16 days ago - Candel Therapeutics Announces Oral Presentation of Positive Phase 3 CAN-2409 Results in Localized Prostate Cancer at ASCO 2025 - GlobeNewsWire
- 5 weeks ago - Candel Therapeutics Announces Publication of Phase 1b Clinical Trial Data on the Combination of CAN-2409 and Nivolumab plus Standard of Care in Newly Diagnosed High-Grade Glioma Patients - GlobeNewsWire
- 6 weeks ago - Candel Therapeutics Reports Both Prolonged Median Overall Survival and Long Tail of Survival in Phase 2a Clinical Trial of CAN-2409 in Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Non-Responsive to Immune Checkpoint Inhibitor (ICI) Treatment - GlobeNewsWire
- 7 weeks ago - Candel Therapeutics and IDEA Pharma Announce Strategic Partnership to Advance Path-to-Market Commercialization Efforts for CAN-2409 - GlobeNewsWire
- 7 weeks ago - Candel Therapeutics Appoints Renowned Pancreatic Cancer Expert, Elizabeth M. Jaffee, M.D. - GlobeNewsWire
- 2 months ago - Candel Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate Highlights - GlobeNewsWire
- 2 months ago - Candel Therapeutics: I Say Stay The Course Despite The Market's Rebuke Of Positive Pancreatic Data - Seeking Alpha